Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) Price Target at $24.27

Shares of Myriad Genetics, Inc. (NASDAQ:MYGNGet Free Report) have earned a consensus rating of “Hold” from the thirteen research firms that are presently covering the stock, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $23.92.

Several equities analysts recently weighed in on MYGN shares. Bank of America dropped their price target on shares of Myriad Genetics from $15.00 to $13.00 and set an “underperform” rating on the stock in a research report on Friday, December 13th. UBS Group assumed coverage on Myriad Genetics in a report on Tuesday, December 10th. They set a “neutral” rating and a $18.00 price target for the company. Stephens restated an “equal weight” rating and set a $20.00 price objective on shares of Myriad Genetics in a research note on Thursday. Morgan Stanley cut their price objective on shares of Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a report on Monday, November 18th. Finally, Piper Sandler lowered their target price on shares of Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, November 11th.

Read Our Latest Analysis on Myriad Genetics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Loomis Sayles & Co. L P raised its stake in Myriad Genetics by 153.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 2,189,601 shares of the company’s stock valued at $59,973,000 after acquiring an additional 1,326,497 shares during the period. Disciplined Growth Investors Inc. MN lifted its stake in shares of Myriad Genetics by 21.1% during the 3rd quarter. Disciplined Growth Investors Inc. MN now owns 2,527,435 shares of the company’s stock valued at $69,226,000 after buying an additional 440,107 shares in the last quarter. Iron Triangle Partners LP bought a new position in Myriad Genetics in the 3rd quarter worth approximately $11,007,000. State Street Corp boosted its holdings in Myriad Genetics by 8.3% in the 3rd quarter. State Street Corp now owns 4,703,442 shares of the company’s stock worth $128,827,000 after buying an additional 359,685 shares during the period. Finally, Point72 Asset Management L.P. grew its stake in Myriad Genetics by 26.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,063,711 shares of the company’s stock valued at $29,135,000 after buying an additional 224,255 shares in the last quarter. Institutional investors own 99.02% of the company’s stock.

Myriad Genetics Trading Down 1.0 %

NASDAQ MYGN opened at $12.39 on Thursday. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The business has a 50 day moving average price of $14.68 and a 200-day moving average price of $21.87. Myriad Genetics has a 52 week low of $12.17 and a 52 week high of $29.30. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -9.53 and a beta of 1.89.

Myriad Genetics Company Profile

(Get Free Report

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.

Further Reading

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.